What is Satellos?
Satellos is a clinical-stage biotechnology company dedicated to the development of small molecule therapeutics designed to restore the body's innate muscle regeneration capabilities. At the core of its operations is the MyoReGenX platform, which targets AAK1, a critical protein involved in the regulation of muscle stem cells. By reactivating natural repair processes that are typically compromised by the absence of dystrophin, Satellos aims to provide a novel therapeutic intervention for patients with limited treatment options. The company's focus on muscle stem cell biology positions it as a key player in the regenerative medicine sector, bridging the gap between fundamental research and scalable clinical applications.
How much funding has Satellos raised?
Satellos has raised a total of $41M across 2 funding rounds:
Corporate Investment
$1M
Other Financing Round
$40M
Corporate Investment (2021): $1M with participation from Parent Project Muscular Dystrophy
Other Financing Round (2024): $40M led by Haywood, Bloom Burton, LeedCo Financial Group, and Canaccord Genuity
Key Investors in Satellos
Bloom Burton
Bloom Burton & Co. specializes in identifying and creating investment opportunities within the healthcare sector, providing capital raising and strategic advisory services to accelerate growth.
Canaccord Genuity
Canaccord Genuity is an independent, full-service financial services firm with extensive operations in wealth management and capital markets, supporting growth-stage companies.
Haywood
Haywood is an established investment bank providing research and strategic advisory services to clients, leveraging decades of market expertise.
What's next for Satellos?
With the infusion of this recent capital, Satellos is expected to prioritize the advancement of its lead therapeutic candidates through rigorous clinical evaluation. The strategic focus will likely center on scaling the MyoReGenX platform and expanding its research capabilities to address a broader spectrum of degenerative muscle diseases. As the company transitions into this next phase of growth, the support from institutional partners will be instrumental in navigating the complexities of drug development and regulatory milestones. Investors and industry stakeholders will be closely monitoring the company's progress as it seeks to validate its therapeutic hypothesis in human clinical trials, potentially setting a new standard for muscle regeneration therapies.
See full Satellos company page
